Giving Kids With Heart Failure a Brighter Future
Giving Kids With Heart Failure a Brighter Future
Katrina Sellens was 14 when a heart pump saved her life. With FDA approval, more kids can benefit from HeartMate 3.
What happened next was also recognizable to Katrina and her family.
She passed out.
Her fainting started when she was 7. By that point, she d lived with the spells for half of her life. Still, Katrina had always been very, very active, said her mother Maria. Roller skating and tennis, horseback riding and camping. A happy kid.
Regular as her fainting had become, this time was different. Very different.
FDA Approves Abbott s HeartMate 3 VAD for Pediatric Patients
HeartMate 3 heart pump approved for use for pediatric patients battling advanced heart failure offering a new treatment option for this underserved population
December 21, 2020 U.S. Food and Drug Administration (FDA) approved updated labeling December 17 for Abbott s HeartMate 3left ventricular assist device (LVAD) to be used in pediatric patients with advanced refractory left ventricular heart failure. With the updated labeling, physicians now have additional options for treating this underserved population awaiting a heart transplant or for those not eligible to receive a transplant as a result of potential complications or risk related to the procedure.
FDA Approves Labeling Update for Abbott s HeartMate 3 Heart Pump for use in Pediatric Patients
- Abbott s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure
- This life-saving technology provides new treatment option for underserved population
News provided by
Share this article
Share this article
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company s HeartMate 3™ heart pump to be used in pediatric patients with advanced refractory left ventricular heart failure. With the updated labeling, physicians now have additional options for treating this underserved population awaiting a heart transplant or for those not eligible to receive a transplant as a result of potential complications or risk related to the procedure.